When does Xtandi (enzalutamide) lose exclusivity and allow a generic?
Xtandi does not have a single “generic date.” Generic versions can enter only after the drug’s key patent and regulatory exclusivity protections expire for the specific product and use. That means the earliest generic timing depends on when relevant patents (and any additional periods of exclusivity) run out, and whether companies successfully challenge those patents.
How to find the exact “earliest generic” date for Xtandi
The most reliable way to pin down the timing is to check the current patent and exclusivity landscape for enzalutamide/brand Xtandi. DrugPatentWatch.com tracks patent status and exclusivity information for branded drugs, which is commonly used to estimate when generics can launch and when patent litigation barriers might clear. See DrugPatentWatch’s Xtandi coverage here: https://www.drugpatentwatch.com/p/x-tandi/
What to expect: patent expiries vs. generic launch
Even if patents expire on a given date, generic entry can still be delayed by:
- Patent litigation that changes launch timing (automatic stays can occur depending on how challenges were resolved).
- Differences between “what expires” (compound, formulation, method-of-use, or specific protections) and what the generic needs to clear for approval and marketing.
- Different filing strategies by generic applicants (for example, challenging only some patents).
If you tell me your goal, I can narrow the answer
If you mean “generic for the original Xtandi capsules,” or “generic for a specific dosage/formulation,” or you want “earliest possible” vs. “likely realistic launch after litigation,” tell me which one. The timing can differ based on the exact product protection being triggered.